Organon Balance Sheet Health
Financial Health criteria checks 0/6
Organon has a total shareholder equity of $-70.0M and total debt of $8.8B, which brings its debt-to-equity ratio to -12514.3%. Its total assets and total liabilities are $12.1B and $12.1B respectively. Organon's EBIT is $1.3B making its interest coverage ratio 2.5. It has cash and short-term investments of $693.0M.
Key information
-12,514.3%
Debt to equity ratio
US$8.76b
Debt
| Interest coverage ratio | 2.5x |
| Cash | US$693.00m |
| Equity | -US$70.00m |
| Total liabilities | US$12.13b |
| Total assets | US$12.06b |
Recent financial health updates
No updates
Recent updates
Little Excitement Around Organon & Co.'s (NYSE:OGN) Earnings
Apr 21
Organon Stock Is Still Worth A Look
Feb 24Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28
Feb 19Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last
Feb 16Organon: What I'm Looking For In This 8% Yield In 2024
Jan 03High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued
Dec 19Organon: It's Darkest Before The Dawn
Nov 30Organon: Poor Q3 Earnings Make Bear Case, But Dividend Is Saving Grace
Nov 07Organon (NYSE:OGN) Has Affirmed Its Dividend Of $0.28
Nov 05Organon: The Federal Reserve Black Swan (Rating Upgrade)
Oct 046% Yield And Significantly Undervalued: A Closer Look At Organon
Sep 10Organon Q2 2023 Earnings Review: Incremental Growth With A Slather Of Risk
Aug 10Organon & Co.: A Tough Spot To Be In Right Now
Jul 16Organon goes ex-dividend tomorrow
Feb 23Organon & Co. (NYSE:OGN) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Feb 19Is There Anything Organic Or Interesting About Organon?
Feb 07Organon goes ex-dividend tomorrow
Nov 09Organon's (NYSE:OGN) Dividend Will Be $0.28
Nov 08Take Care Before Diving Into The Deep End On Organon & Co. (NYSE:OGN)
Nov 05Organon: Thoughts Ahead Of Q3 Earnings
Oct 31Organon: What Is The Recipe?
Aug 31Oragenics announces early toxicology data for intranasal COVID-19 vaccine
Aug 24Organon, Samsung Bioepis Humira biosimilar Hadlima high concentration dosage gets FDA nod
Aug 17Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28
Aug 07Organon Q2 2022 Earnings Preview
Aug 03Organon in pact with Cirqle Biomedical for contraceptive candidate
Jul 28Organon: Some Uncomfortable Questions Ahead Of Q2 Earnings
Jul 18Organon Vs. Viatris: Who Is The Clear Winner?
Jun 20Organon: Maximum Optimism
Apr 28Viatris Vs. Organon: Surprisingly Undervalued, But Which Is The Better Buy?
Feb 19Healthy Dividends: Organon's Dividend Bolsters The Long-Term Investment In A Fresh Ticker
Jan 22Financial Position Analysis
Short Term Liabilities: OGN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: OGN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: OGN has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: OGN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: OGN's debt is not well covered by operating cash flow (9.1%).
Interest Coverage: OGN's interest payments on its debt are not well covered by EBIT (2.5x coverage).